Company news
Nxera Pharma Co., Ltd. (TSE:4565) news
Nxera Pharma Co., Ltd. news releases on 6ix. Latest, Oct 1, 2026: Nxera Announces Successful Resolution of miniG Patent Infringement Action
Press releases & updates
Nxera Announces Successful Resolution of miniG Patent Infringement Action
October 1, 2026
Nxera Pharma to Receive $8.6 Million Milestone Payment from Centessa Pharmaceuticals Following Late-stage Development Progress
September 3, 2026
Nxera Pharma’s Partner Neurocrine Biosciences Receives IND Acceptance from the FDA for Phase 2 Study of NBI-1117567 for Alzheimer's Cognition
August 26, 2026
Nxera Pharma Operational Highlights and Consolidated Results for the Second Quarter 2026
August 7, 2026
Nxera Pharma Webinar for Financial Results Presentation - 2Q2026
July 15, 2026
OpenFold AI Research Consortium Alongside Leading Global Pharmaceutical Companies and Cloud and AI Infrastructure Technology Providers
June 10, 2026
Nxera Pharma : Vamorolone Granted Key Regulatory Designations Supporting Faster Access for Duchenne Muscular Dystrophy Patients in South Korea
June 1, 2026
Nxera’s President & CEO to Participate in a ‘Fireside Chat’ at the Jefferies New York Healthcare Conference 2026
May 26, 2026
Nxera Pharma : Notice of Partial Forfeiture (Decrease in the Number of Shares to be Issued, etc.) in Connection with the Issuance of New Shares Under the RSU Plan
May 18, 2026
Nxera Pharma Announces Progress of Out-Licensing of GPCR-targeted Program and Participation in Series A Financing
May 11, 2026
Nxera Files Patent Infringement Action in Relation to its miniG Platform Technology
May 8, 2026
Nxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2026
May 1, 2026
Santhera Pharmaceuticals Full Year Results for the Year Ended 31 December 2025
April 28, 2026
Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases
April 20, 2026
Notice of Issuance of New Shares in Connection with the Introduction of the Employee Stock Ownership Plan, Matters Relating to Stock Units and Determination of Payment Amount and Other Matters of Issuance of New Shares Under Prior RSU Award
April 15, 2026
Nxera Pharma’s QUVIVIQ® (daridorexant) 25mg and 50mg Receives Approval in Taiwan for the Treatment of Insomnia
April 14, 2026
Nxera Pharma’s Partner Neurocrine Biosciences Doses First Patient in Phase 2 Trial of NBI-1117570 for Adults with Schizophrenia
April 12, 2026
Nxera Pharma Achieves Second Development Milestone in Collaboration with Eli Lilly Targeting Metabolic Diseases
April 8, 2026
Nxera Pharma’s Partner Centessa Pharmaceuticals to be Acquired by Lilly
March 31, 2026
Nxera Pharma : Notice Concerning New Management Structure
March 25, 2026
Full Year 2025 Trading Update
March 12, 2026
Nxera Pharma to Receive US$3 Million Milestone Payment from Centessa Pharmaceuticals
March 5, 2026
Nxera Pharma Submits Marketing Authorization Application for Daridorexant in South Korea
March 4, 2026
Nxera Pharma Proposes Changes to its Board of Directors
February 13, 2026
Nxera Pharma Operational Highlights and Consolidated Results for the Fourth Quarter and Full Year 2025
February 13, 2026
Nxera Pharma to Receive $1.8 Million Milestone Payment from Centessa Pharmaceuticals
February 12, 2026
Nxera Pharma Licenses GPCR-targeted Program to Newly Founded Spin-out Company
February 12, 2026
Nxera Pharma Webinar Presentation for FY2025 Financial Results
January 26, 2026
Nxera Pharma Establishes Metabolic Advisory Council to Advance Next-Generation Therapies for Obesity and Metabolic Disorders
January 20, 2026
Nxera Pharma Reports Positive Results From Phase 3 Trial of Daridorexant in South Korea
January 19, 2026
Nxera Pharma to Receive US$3.6 Million in Milestone Payment Pursuant to Research Collaboration with Centessa
January 13, 2026
Nxera Pharma Licenses Japan and Select Asia-Pacific Rights to Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals
January 8, 2026
Nxera Pharma to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 5, 2026
Nxera Pharma to Regain Full Rights to GPR52 Agonist Program for Schizophrenia
December 18, 2025
Nxera Introduces Employee Stock Ownership Plan (J-ESOP) for Employees Residing in Japan
November 19, 2025
Nxera Pharma Shares Video Interviews with Major Shareholders on Its Official YouTube Channel
November 17, 2025
Nxera Announces Focused Restructuring to Enhance Path to Profitability
November 17, 2025
Nxera Pharma to Host R&D Day 2025
November 4, 2025
Nxera’s President & CEO to Participate in a ‘Fireside Chat’ at the Jefferies London Healthcare Conference 2025
October 31, 2025
Nxera Pharma Receives a Manufacturing Approval Partial Amendment Regarding the Addition of a Manufacturing Site in Asia for QUVIVIQ® 25 and 50 mg
October 31, 2025
Nxera Pharma Operational Highlights and Consolidated Results for the Third Quarter and First Nine Months of 2025
October 31, 2025
Nxera’s Partner Cancer Research UK Presents Data from Successfully Completed Phase 1 Clinical Trial of Cancer Immunotherapy Drug HTL0039732 at ESMO
October 21, 2025
Nxera Pharma and Cancer Research UK Announce First Patient Dosed in Phase 2a Trial of Investigational Cancer Immunotherapy HTL0039732
September 16, 2025
Nxera Pharma Operational Highlights and Consolidated Results for the Second Quarter and First Half 2025
August 8, 2025
Nxera Launches Broad Proprietary Pipeline Targeting Obesity and Chronic Weight Management
August 5, 2025
Nxera Pharma to Receive US$4.8 Million in Milestone Payments Following Centessa’s Initiation of Clinical Development of ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist
July 4, 2025
Nxera Pharma to Receive US$15 Million from Neurocrine Biosciences Following Dosing of First Patient in Phase 3 Trial of NBI-1117568
June 2, 2025
Nxera Pharma Achieves Development Milestone in Collaboration with Eli Lilly Targeting Metabolic Diseases
June 1, 2025
Nxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2025
May 2, 2025
Nxera Pharma’s Partner Neurocrine Biosciences Initiates Phase 3 Registrational Program of NBI-1117568 as a Potential Treatment for Adults with Schizophrenia
April 30, 2025